Solid Biosciences (SLDB) Liabilities and Shareholders Equity (2017 - 2024)
Historic Liabilities and Shareholders Equity for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $211.8 million.
- Solid Biosciences' Liabilities and Shareholders Equity rose 1466.91% to $211.8 million in Q3 2024 from the same period last year, while for Dec 2024 it was $691.5 million, marking a year-over-year decrease of 1179.63%. This contributed to the annual value of $164.9 million for FY2023, which is 3662.33% down from last year.
- Latest data reveals that Solid Biosciences reported Liabilities and Shareholders Equity of $211.8 million as of Q3 2024, which was up 1466.91% from $231.0 million recorded in Q2 2024.
- Solid Biosciences' Liabilities and Shareholders Equity's 5-year high stood at $285.3 million during Q1 2021, with a 5-year trough of $40.5 million in Q3 2020.
- Moreover, its 5-year median value for Liabilities and Shareholders Equity was $208.5 million (2022), whereas its average is $195.4 million.
- In the last 5 years, Solid Biosciences' Liabilities and Shareholders Equity plummeted by 6905.27% in 2020 and then soared by 51450.71% in 2021.
- Solid Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $171.2 million in 2020, then surged by 35.76% to $232.4 million in 2021, then grew by 11.99% to $260.3 million in 2022, then crashed by 36.62% to $164.9 million in 2023, then increased by 28.43% to $211.8 million in 2024.
- Its Liabilities and Shareholders Equity stands at $211.8 million for Q3 2024, versus $231.0 million for Q2 2024 and $248.7 million for Q1 2024.